Nutriband Inc Warrant 2021- on Nutriband NTRBW 深 沪
已收盘 02-06 16:00:00 美东时间
1.65
0.000
0.00%
华盛通- 最 高1.75
- 今 开1.71
- 成交量 191股
- 最 低 1.71
- 昨 收 1.65
- 总市值 0
- 52周最高 4.50
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.80
- 委 比 93.31%
- 总股本 --
- 历史最高 9.07
- 量 比 0.32
- 振 幅 2.42%
- 历史最低 0.1885
- 每 手 1
- 风险率 0.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nutriband CEO Publishes Letter to Shareholders
Nutriband Inc. reported on 2025 achievements including advancing their AVERSA™ Fentanyl patch towards commercialization, securing patents, and enhancing shareholder value through strategic moves like selling a subsidiary and issuing preferred stock dividends. The company also joined four prominent indexes and anticipates reduced stock volatility as warrants from their 2021 IPO expire in 2026. AVERSA™ aims to be the world's first abuse-deterrent o...
2025-12-31 12:00
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
US designates illicit fentanyl as a weapon of mass destruction due to its severe dangers. However, FDA-approved prescription fentanyl patches remain critical for opioid-tolerant patients with severe chronic pain. Nutriband Inc., in collaboration with Kindeva, is developing AVERSA™ FENTANYL, the first abuse-deterrent opioid patch, incorporating aversive agents to prevent misuse and accidental exposure. The technology aims to improve safety while e...
2025-12-18 12:00
Nutriband Founder Gareth Sheridan Returns as CEO to Lead Company Toward 2026 NDA Filing, Serguei Melnik Steps Down
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei
2025-10-27 19:09
Nutriband Co-Founder Gareth Sheridan Returns as CEO
Nutriband Inc. announced that founder Gareth Sheridan has returned as CEO, succeeding Co-Founder Serguei Melnik who led the company from August 10 to October 27. Sheridan will guide Nutriband toward the 2026 NDA filing for AVERSA Fentanyl, an innovative abuse-deterrent opioid patch designed to reduce misuse and accidental exposure. Targeting annual U.S. sales of $80–200 million, AVERSA Fentanyl addresses a global need for safer pain management. T...
2025-10-27 11:00
Nutriband Signs Agreement Brand Institute For AVERSA Fentanyl, Plans To Commercialize Abuse-Deterrent Opioid Patch
Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system.Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and
2025-10-10 19:05
Nutriband Reports 50.87% Revenue Growth, $6.9M Cash; Advances AVERSA Fentanyl Toward NDA With No Phase 2/3 Trials Required
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the
2025-09-10 21:20
Nutriband CEO Gareth Sheridan Steps Aside To Run For Irish Presidency, Chairman Serguei Melnik Takes Helm Ahead Of FDA Milestone
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company CEO, Gareth Sheridan will be stepping aside from his role for three months to enter the Irish Presidential election. The Nomination Hearings followed
2025-08-11 17:07
Nutriband To Issue 25% Preferred Stock Dividend To Shareholders Of Record On July 25, Convertible Upon FDA Approval Of AVERSA Fentanyl
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend.Shareholders of record on July
2025-07-18 21:37
Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
Nutriband Inc. is informing shareholders about upcoming key dates for its 25% Preferred stock dividend. Shareholders of record on July 25, 2025, will receive one preferred share for every four common shares held, with the payout on August 5. Each preferred share is convertible to one common share upon FDA approval of the company's AVERSA Fentanyl product, which uses abuse-deterrent transdermal technology. If unconverted, preferred shares will ear...
2025-07-18 13:15
Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
Nutriband Inc. announced a 25% preferred stock dividend, with eligible shareholders receiving one preferred share for every four common shares held, based on July 25, 2025 records, payable on August 5. Each preferred share is convertible into one common share upon FDA approval of their AVERSA fentanyl product. If unconverted, preferred shares will receive annual cash dividends. The company focuses on developing abuse-deterrent fentanyl patches us...
2025-07-02 12:05
